Featured Research

from universities, journals, and other organizations

Enzyme Is Key To Hallmark Of Alzheimer's -- Moves To Block It Underway

Date:
February 27, 2001
Source:
Johns Hopkins Medical Institutions
Summary:
Scientists at Johns Hopkins have shown that a specific enzyme in the brain is essential for nerve cells to form a hallmark of Alzheimer's disease (AD) — the so-called amyloid plaques that collect and surround brain cells. While aging brains of apparently healthy people contain scattered amyloid plaques, the brains of AD patients are littered with them.

Scientists at Johns Hopkins have shown that a specific enzyme in the brain is essential for nerve cells to form a hallmark of Alzheimer's disease (AD) — the so-called amyloid plaques that collect and surround brain cells. While aging brains of apparently healthy people contain scattered amyloid plaques, the brains of AD patients are littered with them.

Understanding this keystone position of the enzyme beta-secretase marks a significant research step, the scientists say, because blocking the enzyme offers an obvious and — initial studies suggest — a safe target for therapy.

The research is published in the March edition of the journal Nature Neuroscience. It is funded by grants from the National Institute on Aging, Bristol-Myers Squibb Foundation and the Adler Foundation.

"Blocking beta-secretase could have the same effect in people at risk for AD as the vaccines that already are known to keep plaque from forming in tests on lab animals," says lead neuroscientist Philip Wong, Ph.D. "While no research directly links plaque buildup to human AD, blocking plaque does lessen signs of the disease in these animals," Wong says.

"The brain chemistry involved here is virtually identical in mice and humans," says team researcher David Borschelt, Ph.D.

In 1999, five research groups cloned genes for various forms of beta-secretase, but the Hopkins scientists are the first to show that one form of the enzyme (called BACE 1) is key in producing the molecules — within the brain's nerve cells — that become plaque.

In their mouse study, scientists knocked out the gene for their form of beta-secretase. They then cultured nerve cells from the animals' brains and, using antibodies targeted to beta-secretase, confirmed the enzyme wasn't present. Significantly, the Hopkins scientists showed the nerve cells lacking the enzyme failed to form beta amyloid, the plaque protein.

The researchers are also following live mice lacking the gene. "The mice without beta-secretase genes are born apparently normal and seem to suffer no untoward effects, but we're watching them as they age," says Huaibin Cai, Ph.D., another of the researchers. "So far, at eight months, the adult mice appear fine."

"We're really encouraged by possible therapeutic implications," says Wong. "Scientists are already screening for compounds that block the action of beta-secretase in hopes of designing small molecules able to cross the brain's blood-brain barrier." The molecules could, in theory, be fine-tuned to inhibit beta-secretase, Wong adds, which would squelch plaque production. "If that proves therapeutic," he says, "physicians might ultimately give AD patients a "cocktail" of various enzyme-blockers or blockers along with vaccines. "Both approaches may prove useful in treating Alzheimer's," Wong explains.

Beta-secretase works by trimming pieces off a larger molecule that's parent to the plaque protein, beta amyloid. Forming amyloid is a natural cell process, says Wong. It's part of a poorly understood event in cells in which amyloid appears and then is cleared. "But in Alzheimer's," he explains, "something goes wrong and amyloid really increases."

A current hypothesis of AD is that as amyloid builds up, nerve cells are damaged and brain tissues become inflamed. Some researchers believe this chronic inflammation progressively injures nerve cells, leading to the symptoms of the disease.

Scientists say another enzyme, called gamma-secretase, is also involved in brain production of plaque. However, the Hopkins researchers say, the nature of gamma-secretase remains controversial, as does the usefulness of blocking it.

Gamma-secretase is a research hot spot because nearly a quarter of the people with early-onset Alzheimer's have mutations in genes (presenilin genes) linked with the enzyme's activity.

Other members of the research team were Yanshu Wang, Ph.D., Diane McCarthy, Ph.D., Hongjin Wen, M.S. and Donald L. Price, M.D.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Enzyme Is Key To Hallmark Of Alzheimer's -- Moves To Block It Underway." ScienceDaily. ScienceDaily, 27 February 2001. <www.sciencedaily.com/releases/2001/02/010227073721.htm>.
Johns Hopkins Medical Institutions. (2001, February 27). Enzyme Is Key To Hallmark Of Alzheimer's -- Moves To Block It Underway. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2001/02/010227073721.htm
Johns Hopkins Medical Institutions. "Enzyme Is Key To Hallmark Of Alzheimer's -- Moves To Block It Underway." ScienceDaily. www.sciencedaily.com/releases/2001/02/010227073721.htm (accessed September 17, 2014).

Share This



More Mind & Brain News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
'Magic Mushrooms' Could Help Smokers Quit

'Magic Mushrooms' Could Help Smokers Quit

Newsy (Sep. 11, 2014) In a small study, researchers found that the majority of long-time smokers quit after taking psilocybin pills and undergoing therapy sessions. Video provided by Newsy
Powered by NewsLook.com
'Fat Shaming' Might Actually Cause Weight Gain

'Fat Shaming' Might Actually Cause Weight Gain

Newsy (Sep. 11, 2014) A study for University College London suggests obese people who are discriminated against gain more weight than those who are not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins